Key Points
- Insider sale: Carl Dambkowski sold 5,500 shares on Feb 4 at $65.79 for $361,845, reducing his stake by 2.54% to 211,148 shares (valued at about $13.89M); he also sold 18,700 shares on Jan 7 and 10,900 on Dec 4.
- Stock and analyst snapshot: APGE opened at $64.88 and was down 5.8%, trading below its 50‑day MA ($75.43) but above its 200‑day MA ($56.13); market cap is about $4.43B and the consensus rating is Moderate Buy with an average price target of $104.58.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of the business's stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $65.79, for a total transaction of $361,845.00. Following the completion of the sale, the insider directly owned 211,148 shares in the company, valued at $13,891,426.92. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The stock was sold at an average price of $77.84, for a total transaction of $1,455,608.00.
- On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.00, for a total value of $817,500.00.
Apogee Therapeutics Trading Down 5.8%
APGE stock opened at $64.88 on Thursday. The business's fifty day moving average price is $75.43 and its 200 day moving average price is $56.13. Apogee Therapeutics Inc. has a 12-month low of $26.20 and a 12-month high of $84.56. The company has a market capitalization of $4.43 billion, a PE ratio of -14.81 and a beta of 1.42.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.14) by $0.03. Research analysts predict that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP increased its holdings in shares of Apogee Therapeutics by 24.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company's stock valued at $187,673,000 after acquiring an additional 917,991 shares during the last quarter. UBS Group AG boosted its holdings in Apogee Therapeutics by 646.1% in the third quarter. UBS Group AG now owns 799,465 shares of the company's stock valued at $31,763,000 after purchasing an additional 692,308 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Apogee Therapeutics by 27.3% in the fourth quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company's stock valued at $215,709,000 after purchasing an additional 612,193 shares in the last quarter. Jennison Associates LLC purchased a new position in Apogee Therapeutics in the fourth quarter valued at approximately $43,675,000. Finally, Adage Capital Partners GP L.L.C. raised its holdings in Apogee Therapeutics by 77.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,290,464 shares of the company's stock worth $56,045,000 after purchasing an additional 563,464 shares in the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts have commented on APGE shares. Craig Hallum restated a "buy" rating and issued a $116.00 price target on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. Mizuho initiated coverage on Apogee Therapeutics in a research note on Tuesday, October 21st. They set an "outperform" rating and a $105.00 target price for the company. Wolfe Research started coverage on Apogee Therapeutics in a report on Wednesday, January 7th. They set a "peer perform" rating on the stock. Citigroup reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Sunday, January 25th. Finally, Wall Street Zen downgraded Apogee Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, December 6th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $104.58.
Read Our Latest Stock Report on Apogee Therapeutics
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
